Clinical Trials

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

60 enrolled

Lymphoma, Recurrence

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

Recurrence, Lymphoma, B-Cell

NCT01593488 2023-03-24

CILI

CNSLymphoidOther hematologic neoplasm

31 enrolled

Central Nervous System Diseases, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

33 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04113226 2023-02-08

Relyage

114 enrolled

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT04887025 2023-02-06

Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

25 enrolled

Recurrence, Lymphoma, B-Cell

NCT05585996 2023-02-06

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

70 enrolled

Recurrence, Lymphoma, B-Cell

NCT05557903 2022-09-28

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

71 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT05527275 2022-09-02

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

78 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT05495100 2022-08-10

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

45 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT05363800 2022-07-29

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

198 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT05212584 2022-07-06

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

24 enrolled

Leukemia, Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05320081 2022-04-11

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

30 enrolled

Lymphoma, Recurrence

NCT04989621 2022-03-24

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

32 enrolled

Lymphoma, Follicular, Recurrence

NCT05155839 2022-02-22

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

108 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT05223686 2022-02-04

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

18 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05137860 2022-01-18

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Phase 4 Unknown

56 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05137886 2021-12-17

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

47 enrolled

Hodgkin Disease, Recurrence

NCT04948788 2021-09-28

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

102 enrolled

Recurrence, Lymphoma, B-Cell

NCT04458389 2021-08-13

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

268 enrolled

Lymphoma, Recurrence

NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Lymphoma, Recurrence

NCT04539444 2021-08-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

10 enrolled

Lymphoma, Non-Hodgkin, Recurrence

NCT03245905 2021-03-16

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

100 enrolled

Recurrence, Lymphoma, B-Cell

NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

33 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT03265106 2021-02-04

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04204161 2021-02-04

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

30 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04108325 2021-01-28

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

58 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT04723901 2021-01-26

CAR-T

Burkitt Lymphoma, Recurrence

NCT04723914 2021-01-26

CAR-T

Lymphoma, Recurrence, Lymphoma, B-Cell

NCT03474133 2020-07-21

BASALT

80 enrolled

Hodgkin Disease, Recurrence

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

44 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04109872 2020-02-05

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Unknown

25 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT02267915 2020-01-27

MAN2

36 enrolled

Phase EARLY_PHASE1 Unknown

Recurrence, Lymphoma, Mantle-Cell

NCT04169932 2019-11-20

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma